

# Annelieke E C A B Willemsen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8345904/publications.pdf>

Version: 2024-02-01

16  
papers

347  
citations

1051969

10  
h-index

1051228

16  
g-index

17  
all docs

17  
docs citations

17  
times ranked

726  
citing authors

#	ARTICLE	IF	CITATIONS
1	Baseline effector cells predict response and NKT cells predict pulmonary toxicity in advanced breast cancer patients treated with everolimus and exemestane. <i>International Immunopharmacology</i> , 2021, 93, 107404.	1.7	2
2	Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane. <i>Targeted Oncology</i> , 2019, 14, 441-451.	1.7	11
3	Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations. <i>British Journal of Cancer</i> , 2019, 121, 34-36.	2.9	16
4	Clinical validation study of dried blood spot for determining everolimus concentration in patients with cancer. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 465-471.	0.8	20
5	Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. <i>Targeted Oncology</i> , 2018, 13, 641-648.	1.7	10
6	Everolimus exposure and early metabolic response as predictors for treatment outcomes in breast cancer patients treated with everolimus and exemestane.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1062-1062.	0.8	0
7	Nivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma: A Case Report. <i>Journal of Immunotherapy</i> , 2017, 40, 345-348.	1.2	61
8	mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm. <i>International Journal of Cancer</i> , 2016, 138, 2312-2321.	2.3	76
9	A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1447-1456.	1.6	17
10	Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors. <i>Drug Discovery Today</i> , 2016, 21, 962-976.	3.2	46
11	Positron emission tomography response criteria in solid tumours criteria for quantitative analysis of [ 18 F]-fluorodeoxyglucose positron emission tomography with integrated computed tomography for treatment response assessment in metastasised solid tumours: All that glitters is not gold. <i>European Journal of Cancer</i> , 2016, 56, 54-58.	1.3	9
12	Caution for interstitial lung disease as a cause of CA 15â€³ rise in advanced breast cancer patients treated with everolimus. <i>International Journal of Cancer</i> , 2014, 135, 1007-1007.	2.3	6
13	Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor. <i>Acta Neuropathologica Communications</i> , 2014, 2, 41.	2.4	47
14	Diagnostic challenges of respiratory adverse events during everolimus treatment. <i>Targeted Oncology</i> , 2014, 9, 287-291.	1.7	6
15	mTOR inhibitor-related pulmonary toxicity; incidence even higher. <i>Acta OncolÃ³gica</i> , 2013, 52, 1234-1234.	0.8	4
16	Fatal thrombotic microangiopathy after a single dose of gemcitabine as fourth-line palliative treatment for metastasized ductal breast carcinoma. <i>Acta OncolÃ³gica</i> , 2011, 50, 462-465.	0.8	14